Literature DB >> 30046420

Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymes.

Michael Hugh Miller1, Andrew Fraser2, Gillian Leggett2, Alastair MacGilchrist3, George Gibson4, James Orr4, Ewan H Forrest4, Ellie Dow5, William Bartlett5, Chirstopher Weatherburn5, Axel Laurell1, Kirsty Grant1, Kathryn Scott6, Ronald Neville5, John F Dillon1.   

Abstract

BACKGROUND: Liver function tests (LFTs) are commonly abnormal; most patients with 'incidental' abnormal LFTs are not investigated appropriately and for those who are, current care pathways are geared to find an explanation for the abnormality by a lengthy process of investigation and exclusion, with costs to the patient and to the health service.
OBJECTIVE: To validate an intelligent automatable analysis tool (iLFT) for abnormal liver enzymes, which diagnoses common liver conditions, provides fibrosis stage and recommends management.
DESIGN: A retrospective case note review from three tertiary referral liver centres, with application of the iLFT algorithm and comparison with the clinician's final opinion as gold standard.
RESULTS: The iLFT algorithm in 91.3% of cases would have correctly recommended referral or management in primary care. In the majority of the rest of the cases, iLFT failed safe and recommended referral even when the final clinical diagnosis could have been managed in primary care. Diagnostic accuracy was achieved in 82.4% of cases, consistent with the fail-safe design of the algorithm. Two cases would have remained in primary care as per the algorithm outcome, however on clinical review had features of advanced fibrosis.
CONCLUSION: iLFT analysis of abnormal liver enzymes offers a safe and robust method of risk stratifying patients to the most appropriate care pathway as well as providing reliable diagnostic information based on a single blood draw, without repeated contacts with health services. Offers the possibility of high quality investigation and diagnosis to all patients rather than a tiny minority.

Entities:  

Keywords:  liver function test

Year:  2018        PMID: 30046420      PMCID: PMC6056084          DOI: 10.1136/flgastro-2017-100909

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  15 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

2.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

Review 3.  A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes.

Authors:  Sven Radcke; John F Dillon; Aja L Murray
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 2.566

4.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

Authors:  Julie Parkes; Paul Roderick; Scott Harris; Christopher Day; David Mutimer; Jane Collier; Martin Lombard; Graeme Alexander; John Ramage; Geoffrey Dusheiko; Mark Wheatley; Carol Gough; Alastair Burt; William Rosenberg
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

5.  Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.

Authors:  Tania M Welzel; Neeru Bhardwaj; Charlotte Hedskog; Krishna Chodavarapu; Gregory Camus; John McNally; Diana Brainard; Michael D Miller; Hongmei Mo; Evguenia Svarovskaia; Ira Jacobson; Stefan Zeuzem; Kosh Agarwal
Journal:  J Hepatol       Date:  2017-03-24       Impact factor: 25.083

Review 6.  The epidemiology of non-alcoholic fatty liver disease.

Authors:  Stefano Bellentani
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

7.  Extensive testing or focused testing of patients with elevated liver enzymes.

Authors:  Elliot B Tapper; Sameer D Saini; Neil Sengupta
Journal:  J Hepatol       Date:  2016-10-04       Impact factor: 25.083

8.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).

Authors:  P T Donnan; D McLernon; J F Dillon; S Ryder; P Roderick; F Sullivan; W Rosenberg
Journal:  Health Technol Assess       Date:  2009-04       Impact factor: 4.014

Review 10.  Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

Authors:  Rebecca Harris; David J Harman; Timothy R Card; Guruprasad P Aithal; Indra Neil Guha
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-02-01
View more
  5 in total

1.  Multiple symptoms, multiple systems.

Authors:  Anton V Emmanuel
Journal:  Frontline Gastroenterol       Date:  2018-06-07

Review 2.  Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review.

Authors:  Paul Brennan; Kathleen Clare; Jacob George; John F Dillon
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

3.  Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C.

Authors:  A McLeod; S J Hutchinson; A Weir; S Barclay; J Schofield; C Gillespie Frew; D J Goldberg; M Heydtmann; E Wilson-Davies
Journal:  Epidemiol Infect       Date:  2022-06-27       Impact factor: 4.434

4.  The Development and Implementation of a Commissioned Pathway for the Identification and Stratification of Liver Disease in the Community.

Authors:  J Chalmers; E Wilkes; R Harris; L Kent; S Kinra; G P Aithal; M Holmes; J Johnson; J R Morling; I N Guha
Journal:  Frontline Gastroenterol       Date:  2019-06-26

5.  An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.

Authors:  Lucy Gracen; Kelly L Hayward; Melanie Aikebuse; Suzanne Williams; Anthony Russell; James O'Beirne; Elizabeth E Powell; Patricia C Valery
Journal:  Diabet Med       Date:  2022-02-07       Impact factor: 4.213

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.